There are currently 26 active clinical trials seeking participants for Interstitial Lung Disease research studies. The states with the highest number of trials for Interstitial Lung Disease participants are California, Texas, Florida and New York.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: UAB Lung Health Center, Birmingham, Alabama +45 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
NCT04624490
Recruiting
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
Gender:
All
Ages:
3 years and above
Trial Updated:
06/07/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Register for Updates
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/04/2024
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +102 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
NCT03814317
Recruiting
This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/24/2024
Locations: University of Florida, Division of Pulmonary and Critical Care Medicine, Gainesville, Florida
Conditions: Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Pulmonary Associates, Phoenix, Arizona +23 locations
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668
Recruiting
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: Mayo Clinic - Scottsdale ( Site 4014), Phoenix, Arizona +73 locations
Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Register for Updates
FAPI PET for Lung Fibrosis
NCT05365802
Recruiting
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis, Radiation Pneumonitis, Pneumoconiosis, Pulmonary Fibrosis
Register for Updates
Genentech Validation Tool for Pulmonary Fibrosis
NCT04676594
Recruiting
Radiology is an important component of the multidisciplinary team. The primary goal of this project will be to create a tool using findings on chest computed tomography (CT) for nearly 300 patients with the most common types of fibrosis. The tool will be tested using chest CT scans of an additional 100 patients with the 3 most common diagnoses of fibrosis. The second objective will be to further validate the tool by performing a reader study with 3 co-investigating radiologists and ask them to l... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
04/30/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Interstitial Lung Disease
Register for Updates
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
NCT06397677
Recruiting
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/29/2024
Locations: University of California San Francisco, San Francisco, California +3 locations
Conditions: Rheumatoid Arthritis, Interstitial Lung Disease
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
NCT05892614
Recruiting
This is a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1 of 2 active (experimental) d... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: aTyr Investigative Site, Los Angeles, California +14 locations
Conditions: Interstitial Lung Disease
Register for Updates
Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough
NCT05120934
Recruiting
This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/29/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Interstitial Lung Disease
Register for Updates
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
NCT03478826
Recruiting
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Interstitial Lung Disease
Register for Updates